Auriclosene

Drug Profile

Auriclosene

Alternative Names: AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator NovaBay Pharmaceuticals
  • Developer Alcon; Galderma; NovaBay Pharmaceuticals
  • Class Alkanesulfonic-acids; Anti-infectives; Antibacterials; Antifungals; Chloramines; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Impetigo
  • Phase II Infectious conjunctivitis; Urinary tract infections
  • Preclinical Escherichia coli infections; Klebsiella infections; Onychomycosis
  • No development reported Acne; Staphylococcal infections
  • Discontinued Otorhinolaryngological infections

Most Recent Events

  • 19 Sep 2016 NovaBay Pharmaceuticals has composition of matter patent protection for Auriclosene in USA up to 2028
  • 19 Sep 2016 Interim adverse events and efficacy data from a phase IIb trial in Urinary tract infections released by NovaBay Pharmaceuticals
  • 11 Aug 2016 Auriclosene is available for licensing as of 23 Sep 2016. http://novabay.com/partners/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top